不可切除胰腺癌的分子靶向药物治疗进展

Advances in molecular-targeted therapy for unresectable pancreatic cancer

胰腺癌作为消化系统最常见的恶性肿瘤之一,其发病率及死亡率正逐年上升,大多数胰腺癌患者因分期较晚而失去了手术机会。尽管以吉西他滨、氟尿嘧啶为主的化疗方案在一定程度上延长了患者的生存期,但仍有部分患者因无法耐受化疗而失去治疗机会。随着精准医疗时代的来临,分子靶向药物治疗展现出的优异疗效使其成为对抗肿瘤的重要治疗手段之一,但由于胰腺癌高度的异质性及复杂的免疫微环境,针对胰腺癌的分子靶向治疗并未取得显著效果,因此亟需探寻新的治疗靶点及药物攻克这一难题。本综述基于胰腺癌常见分子靶点及肿瘤免疫相关靶点探究在不可切除胰腺癌中分子靶向药物治疗研究的最新进展,为胰腺癌患者提供新的治疗策略。

Pancreatic cancer is one of the most prevalent malignant tumors of the digestive system,and its incidence and mortality rates are increasing year by year.Most patients with pancreatic cancer are unable to receive surgery due to the advanced stage.Although chemotherapy regimens based on gemcitabine and fluorouracil have prolonged the survival time of patients to some extent,some patients cannot tolerate chemotherapy and hence lose the opportunity for treatment.With the advent of the era of precision medicine,molecular-targeted therapy has exhibited an excellent therapeutic efficacy and has thus become one of the most important treatment techniques for tumors;however,due to the high heterogeneity of pancreatic cancer and its complicated tumor microenvironment,molecular-targeted therapy for pancreatic cancer has not achieved notable results.Therefore,it is imperative to seek new therapeutic targets and medications to overcome this issue.This article reviews the latest advances in the research on molecular-targeted therapy for unresectable pancreatic cancer based on common molecular targets and tumor immunity-related therapeutic targets,in order to provide new treatment strategies for patients with pancreatic cancer.